NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference

Impact · against what's priced in

NeoGenomics demonstrates strong operational momentum in NGS and MRD, though much of the immediate growth is tied to revenue-cycle management rather than pure volume. While the expanded addressable market for RaDaR ST is a positive development, the lack of immediate material contribution from liquid biopsy through 2027 limits short-term upside.

NEO+0.50

No priced-in read yet